News articles about Neos Therapeutics (NASDAQ:NEOS) have trended positive on Sunday, Accern reports. The research group ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Neos Therapeutics earned a coverage optimism score of 0.28 on Accern’s scale. Accern also gave media stories about the company an impact score of 43.7128055060738 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

A number of equities analysts have weighed in on the stock. BidaskClub lowered shares of Neos Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 17th. BMO Capital Markets lowered shares of Neos Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 31st. Zacks Investment Research lowered shares of Neos Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 25th. Finally, Cantor Fitzgerald set a $20.00 price target on shares of Neos Therapeutics and gave the stock a “buy” rating in a research report on Monday, January 8th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Neos Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $14.00.

Neos Therapeutics (NASDAQ NEOS) traded up $0.15 during mid-day trading on Friday, hitting $8.45. 264,417 shares of the stock traded hands, compared to its average volume of 292,515. Neos Therapeutics has a 1 year low of $5.80 and a 1 year high of $13.15. The company has a debt-to-equity ratio of 4.01, a current ratio of 2.42 and a quick ratio of 2.14. The stock has a market capitalization of $245.02, a P/E ratio of -2.47 and a beta of -0.20.

TRADEMARK VIOLATION NOTICE: “Neos Therapeutics (NEOS) Receiving Positive Media Coverage, Accern Reports” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Insider Buying and Selling by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with's FREE daily email newsletter.